WebSeminar: New framework conditions for biotech & life sciences in the US
This web-seminar is part of our international "Biotech Goes Global" series, designed to open doors to key global markets. This session’s spotlight: The United States. The economic and regulatory landscape in the US has changed under the new administration. What impact does this have on European biotech and life science companies? What new hurdles are there - and where might new opportunities even arise?
This session will address essential aspects for companies in the health sector (including biotechnology, pharmaceuticals, medical technology, and digital health) interested in learning more about the sector in the US, which is the most advanced and diversified life sciences and healthcare ecosystems in the world.
This session focuses on:
- A brief market update and business outlook
- Chances and risks for international Life Science Start-ups
- What has changed for international trade?
- Changes within the regulatory framework - what is new with the FDA
Speakers:
- Timo Rehbock, Barnes & Thornburg
- Matthias Amberg, Rödl & Partner
- Marc Filerman, Start2 Group
- Christine Sohar Henter, Barnes & Thornburg
- Ulrich Granzer, Granzer Consulting
Agenda:
15:00 - Introduction by BioM
15:05 - Market update and business outlook - Barnes & Thornburg / Rödl & Partner
15:30 - Chances and risks for international Life Science Start-ups - Start2 Group
15:45 - Tariffs, trade war, and more international trade topics - Barnes & Thornburg
16:00 - Changes within the regulatory framework - Granzer Consulting
16:15 - Discussion and Q&A
Registration: Participation is free of charge, but registration is required. Register electronically using the registration form below.